论文信息 - 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study - 字舞流文

611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study

R. Berger | J. Bono | E. Antonarakis | U. Vaishampayan | K. Tabata | T. Alanko | J. Piulats | C. Poehlein | R. Wit | A. Omlin | S. Feyerabend | S. Fukasawa | J. Goh | C. Hoimes | Cuizhen Niu | A. Sezer | C. Schloss | K. Ojamaa | J. Yachnin | M. Gross-Goupil